STAT5B and hematopoietic and lymphoid cell neoplasm: Activating STAT5B mutations, particularly STAT5BN642H, have been identified in T-cell large granular lymphocytic leukemia and other hematologic cancers, where they drive constitutive JAK–STAT signaling and malignant proliferation [14,15,18,19].